Dapagliflozin

The FDA has approved the SGLT2 inhibitor dapagliflozin for patients with heart failure with reduced injection fraction regardless of diabetes status. It was the top story in cardiology last week.

AstraZeneca announced the FDA has approved its SGLT2 inhibitor dapagliflozin to reduce risk for CV death and HF hospitalization in patients with HF with reduced ejection fraction with and without type 2 diabetes.

AstraZeneca announced the FDA has approved its SGLT2 inhibitor dapagliflozin to reduce risk for CV death and HF hospitalization in patients with HF with reduced ejection fraction with and without type 2 diabetes.

A global phase 3 trial is underway to assess the potential of dapagliflozin as a treatment to reduce COVID-19 progression among adults with cardiovascular, metabolic or renal risk factors. It was the top story last week in endocrinology.

Recruitment for a global phase 3 trial is now underway to assess the potential of the SGLT2 inhibitor dapagliflozin as a treatment to reduce COVID-19 progression, complications and death among adults with cardiovascular, metabolic or renal risk factors, according to a press release from AstraZeneca and St. Luke’s Mid America Heart Institute.

The phase 3 DAPA-CKD trial assessing the benefit of the SGLT2 inhibitor dapagliflozin in adults with chronic kidney disease will be stopped early after investigators reported an “overwhelming benefit” for reduction in worsening renal function or renal death compared with placebo, according to a press release from AstraZeneca.

Researchers found that high-risk patients with diabetes who were treated with dapagliflozin experienced a decrease in atrial fibrillation and atrial flutter incidences. It was the week’s top story in cardiology.

An investigational, once-daily pill added to optimized insulin therapy was shown to reduce HbA1c among adults with type 1 diabetes during a 12-week trial when compared with placebo plus insulin, according to a press release from vTv Therapeutics.

High-risk patients with diabetes who were treated with dapagliflozin had a decrease in the incidence of atrial fibrillation and atrial flutter, according to an analysis of the DECLARE-TIMI 58 trial published in Circulation.

PHILADELPHIA — Treatment with the SGLT2 inhibitor dapagliflozin was not associated with a reduction in mean lung fluid volume among adults with HF with reduced ejection fraction compared with placebo.